Sagimet Biosciences Series Stock Net Income
| SGMT Stock | 5.36 0.33 5.80% |
Sagimet Biosciences Series fundamentals help investors to digest information that contributes to Sagimet Biosciences' financial success or failures. It also enables traders to predict the movement of Sagimet Stock. The fundamental analysis module provides a way to measure Sagimet Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sagimet Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -26.9 M | -28.3 M | |
| Net Loss | -13.1 M | -13.7 M | |
| Net Loss | -27.9 M | -29.3 M | |
| Net Loss | (2.66) | (2.80) |
Sagimet | Net Income |
Sagimet Biosciences Series Company Net Income Analysis
Sagimet Biosciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sagimet Biosciences Net Income | (27.88 M) |
Most of Sagimet Biosciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sagimet Biosciences Series is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sagimet Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sagimet Biosciences Series reported net income of (27.88 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Sagimet Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sagimet Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sagimet Biosciences could also be used in its relative valuation, which is a method of valuing Sagimet Biosciences by comparing valuation metrics of similar companies.Sagimet Biosciences is currently under evaluation in net income category among its peers.
Sagimet Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sagimet Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sagimet Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Sagimet Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (18.14) % | ||||
| Current Valuation | 30.82 M | ||||
| Shares Outstanding | 30.67 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 70.06 % | ||||
| Number Of Shares Shorted | 4.36 M | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 89.18 X | ||||
| Revenue | 2 M | ||||
| EBITDA | (30.74 M) | ||||
| Net Income | (27.88 M) | ||||
| Total Debt | 65 K | ||||
| Book Value Per Share | 5.74 X | ||||
| Cash Flow From Operations | (23.77 M) | ||||
| Short Ratio | 1.37 X | ||||
| Earnings Per Share | (0.92) X | ||||
| Target Price | 32.6 | ||||
| Market Capitalization | 191.24 M | ||||
| Total Asset | 96.72 M | ||||
| Retained Earnings | (249.74 M) | ||||
| Working Capital | 90.99 M | ||||
| Net Asset | 96.72 M |
About Sagimet Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sagimet Biosciences Series's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sagimet Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sagimet Biosciences Series based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.